Introduction
============

Oral cancer is one of the most common head and neck malignant tumors all around the world. Among them, tongue squamous cell carcinoma (TSCC) accounts for approximately 25% to 40% of oral cancers [@B1]. Surgical resection combined with chemotherapy and radiotherapy has been used as the primary clinic treatment for TSCC. In spite of recent progresses of operation, chemotherapy and radiotherapy, TSCC has a high risk of developing secondary or recurrent tumors in the surrounding area. So the overall mortality rate remains high, and the 5-year survival rate of TSCC patients is less than 50% [@B2]. Local trauma, tobacco and areca hobbies play important roles in the development of TSCC [@B3], [@B4]. The same as other human tumors, the occurrence and development of TSCC is a multi-step process that involves oncogene activation and tumor suppressor silencing [@B5]-[@B15]. Increasing evidences suggest a close association between genetic and epigenetic alterations and TSCC [@B16]. Discovering suitable biomarkers is a key to monitor cancer recurrence or screening high-risk TSCC populations, which will be helpful to guide adjuvant or neoadjuvant therapy of TSCC.

Long non-coding RNAs (lncRNAs) are newly-identified class of RNAs that are more than 200 nucleotides in length and have been considered to be the "noise" of gene transcription because of their absence of protein-encoding ability [@B17]. However, accumulating evidence indicates that they participate in many physiological processes, such as carcinogenesis [@B18]-[@B29], by modulating gene expression at the epigenetic, transcriptional and posttranscriptional levels. LncRNAs appear to participate in all stages of cancer development, including tumor initiation, progression and metastasis, and the dysregulation of lncRNAs are a primary feature of some human cancers [@B21]. Profiling LncRNA expression is a powerful strategy to screen dysregulated lncRNAs and to identify novel prognostic factors in cancer [@B18]. To date, more than 50,000 lncRNAs have been reported in the human genome; however, the function of most of these lncRNAs remains unknown.

In this study, we performed gene expression profiling analysis by mining two online TSCC data sets (GSE9844 [@B30] and GSE30784 [@B31]), based on Affymetrix gene expression microarray platform. One lncRNA, long intergenic non-coding RNA 152 (LINC00152, NCBI accession number: NR_024204, Affymetrix probe set: 225799_at) was significantly overexpressed in TSCC. Then, we examined its expression in fresh TSCC biopsies and paraffin-embedded tissues by Quantitative Real time PCR (qRT-PCR) and *in situ* hybridization, respectively. LINC00152 was highly expressed TSCC, and increased expression of LINC00152 was significantly correlated with TSCC progression, relapse and poor prognosis. These findings provided a novel insight concerning the role of LINC00152 in the progression of TSCC.

Material and methods
====================

Tissue samples
--------------

Two sets of TSCC samples were collected for this study: Set 1 for qRT-PCR, containing 15 TSCC and 14 non-tumor lingual mucous membrane biopsies; Set 2 for *in situ*hybridization, including 182 paraffin-embedded TSCC and 46 non-tumor lingual mucous membrane tissue samples to confirm the expression of LINC00152. In brief, after surgical removal of the tongue cancer tissues, the tissues were washed three times in glucose-containing Hank\'s Balanced Salt Solution (HBSS). The fat and fiber tissue were trimmed out [@B32]. All specimens were confirmed by histopathological examination. All of patients were complete remission after surgical resection combined with chemotherapy. All tissue samples were acquired with approval of patients and the protocol was reviewed and approved by the Ethics Committee at the Affiliated Cancer Hospital of Central South University.

Data mining and analysis
------------------------

Two independent cohorts of primary TSCC gene expression profiling (GEP) data based on the Affymetrix Human Genome U133 Plus 2.0 platform and their correlated clinic data, GSE9844 [@B30] and GSE30784 [@B31] were obtained from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>). GSE30784 has 167 cancer tissues and 45 normal adjacent tissues. GSE9844 contain 26 cancer tissues and 12 normal adjacent tissues. Significant Analysis of Microarray (SAM) software [@B33]-[@B35] were used to analyze normal lingual mucous membrane and TSCC tissue samples for differences in the expression of lncRNAs in these two published TSCC dataset. The cut-off value for differentially expressed lncRNA was set at ≥ 1.5-fold or ≤ 0.67-fold change and the false discovery ratio (FDR) was \< 0.05. The data analysis procedures are shown in **Figure [1](#F1){ref-type="fig"}A**.

RNA isolation and qRT-PCR
-------------------------

Total RNA was extracted from frozen tissues using an RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse transcribed into cDNA according to the manufacturer\'s instructions [@B36]-[@B42]. One μg of total RNA was reverse transcribed to cDNA using a Reverse Transcription Kit (Biorad, Hercules, CA, USA). qRT-PCR was performed with SYBR Green (Biorad) in the CFX96 Real-Time PCR Detection System (Bio-Rad) to determine the relative expression levels of target genes. The primers used were LINC00152: 5\'-TTGATGGCTTGAACATTTGG-3\' and 5\'-TCG TGATTTTCGGTGTCTGT-3\'; *ACTB* (β-actin): 5\'-TCACCAACTGGGACGACATG -3\' and 5\'-GTCACCGGAGTCCATCACGAT-3\'. *ACTB*was used as the reference and normalization control [@B43], [@B44]. The average of three independent analyses for each gene was calculated. Relative expression was calculated using the equation: ΔCt = Ct (LINC00152) - Ct (ACTB), fold expression = 2^-(ΔCt(tumor)\ -\ ΔCt(normal))^.

*In situ*hybridization
----------------------

*In situ*hybridization was performed to detect LINC00152 expression as previously described [@B45]-[@B48]. Three probes from different LINC00152 regions (5\'-CTATGTCTTAATCCCT TGTCCTTCATTAAAAGC-3\', 5\'-CTTCATTGAACA GTTTGTATATTGGAAACTTGCC-3\', and 5\'-GCTGCTTTTAAGTTTCAAATTGACATTCCAGAC-3\') were synthesized and labeled with DIG-dUTP at the 3\' end (Invitrogen, Shanghai, China). Three *GAPDH* probes used as positive controls were 5\'-CCACTTTACCAGAGTTAAAAGCAGCCCTGG-3\', 5\'-CAGTAGAGGCAGGG ATGATGTTCTGGAGAG-3\', and 5\'-GTCAGAGGAGACCACCTGGTGCTCAGT GTA-3\'. A semi-quantitative scoring criterion for in situ hybridization was used in which both the staining intensity and the number of positive cells were recorded. The scoring was graded as 0 (negative), 1 (\< 10% positive), 2 (10% - 50% positive), or 3 (\> 50% positive) in accordance with the staining proportion and intensity. The final scores were regarded as low expression (0-1) and high expression (2-3). The scores corresponding to the overall distribution of LINC00152 were averaged across the different tumor plugs in each case. All sections were independently scored by two pathologists who were blinded to the clinicopathological features and the clinical data.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS software, version 19.0 (SPSS, Chicago, IL, USA). Student\'s *t*-tests were used to evaluate significant differences between any two groups of data and one way ANOVA were used to evaluate significant differences for multiple comparisons. Overall survival (OS) or relapse-free survival (RFS) were calculated using the Kaplan-Meier method, and the results of the analysis were considered significant in a log-rank test if *p***\<**0.05. All data are represented as means ± standard deviation. A two-tailed *p*value of 0.05 or less was considered statistically significant. The graphs were plotted using Graph-Pad Prism 6.0 (Graph-Pad Software, La Jolla, CA).

Results
=======

LncRNA expression profiles in TSCC tissues
------------------------------------------

Firstly, we analyzed the profiles of TSCC patient from Gene Expression Omnibus (GEO) [@B33], datasets GSE9844 and GSE30784, and found that there were 1931 differentially expressed genes of the GSE30784 dataset and 759 of the GSE9844 dataset in TSCC patients compared with normal lingual mucous membrane (Figure [1](#F1){ref-type="fig"}A). Through aggregation of differentially expressed lncRNAs signatures from these two GEO datasets, 12 overlapping probe sets, representing 12 lncRNAs genes were identified, which included 6 upregulated and 6 downregulated lncRNAs (Figure [1](#F1){ref-type="fig"}B). Most of them were unknown and not well identified, such as SNHG5, LINC00520, LINC00094, LINC00511, EPB41L4A-AS1, and LINC00341. H19, a well-known lncRNA that has been identified in multiple cancers, was also down-regulated in TSCC samples among these overlapping probe sets.

Expression of LINC00152 in TSCC and non-cancerous lingual mucous membrane
-------------------------------------------------------------------------

Among the differentially expressed lncRNAs, LINC00152 expression was one of the most significantly overexpressed in the TSCC tissues compared to adjacent non-tumor tissues according to the GS30784 and GSE9844 datasets (**Figure [2](#F2){ref-type="fig"}A & 2B**;*p*\< 0.001 and *p* = 0.044, respectively). To confirm the role of LINC00152 in TSCC progression, we detected the LINC0152 expression levels in 15 TSCC tissues and 14 adjacent non-tumor tissues using by qRT-PCR, and normalizing to β-actin. Results showed that the transcript levels of LINC00152 in TSCC tissues was significantly high compared to that in adjacent normal tissues (*p* = 0.043, **Figure [2](#F2){ref-type="fig"}C**), which was consistent with the GEO datasets.

Correlations between aberrant expression of LINC00152 and TSCC clinical pathological parameters
-----------------------------------------------------------------------------------------------

We next assessed LINC00152 expression in 182 paraffin embedded TSCC samples and 46 adjacent non-tumor tissues via *in situ* hybridization. Representative images of LINC00152 signals are shown in **Figure [3](#F3){ref-type="fig"}A**. The data showed that LINC00152 was highly expressed in 52.2% (95 of 182) cancerous tissues compared with 28.3% (13 of 46) adjacent non-tumor tissues (*p*= 0.004, **Figure [3](#F3){ref-type="fig"}B**). Then we examined the correlation of LINC00152 expression level with patients\' clinical features in TSCC, such as gender, age, smoking, chewing areca, pathological stage, tumor size (T stage), lymph-vascular invasion (N stage), invasion muscles of tongue, and relapse. As shown in **Figure [3](#F3){ref-type="fig"}**, high LINC00152 expression was positively correlated with T stage (*p =*0.009, **Figure [3](#F3){ref-type="fig"}C**), lymph node metastasis (*p*= 0.036, **Figure [3](#F3){ref-type="fig"}D**), higher TNM stage (*p =*0.017, **Figure [3](#F3){ref-type="fig"}E**), relapse (*p \<*0.001, **Figure [3](#F3){ref-type="fig"}F**), and invasion muscles of tongue (*p*\< 0.001, **Figure [3](#F3){ref-type="fig"}G**). However, other clinical parameters, such as gender, age, smoking and chewing areca, were found not to be significantly correlated with LINC00152 expression in this study.

LINC00152 upregulation is associated with poor prognosis in TSCC
----------------------------------------------------------------

To explore the relationship between LINC00152 expression and TSCC patients\' prognosis, we assessed the correlation between LINC00152 expression and clinical outcomes. The results of Kaplan-Meier analysis showed that the median overall survival (OS) time was 35 and 28 months in TSCC patients with low and high expression of LINC00152, respectively (**Figure [4](#F4){ref-type="fig"}A**, *p* = 0.006). While the median relapse-free survival (RFS) time of TSCC patients with low and high expression of LINC00152 was 29 and 26.5 months, respectively (**Figure [4](#F4){ref-type="fig"}B**, *p* = 0.007).

Discussion
==========

Many studies have reported a close association between lncRNA expression and tumor development and progression. The GEO database is a public gene expression data repository that has collected a large amount of gene expression data and serves as a valuable data source for biomedical research. Mining of published high throughput data is a commonly used and low-cost method to identify novel biomarkers [@B49]. The Affymetrix HG-U133 plus 2.0 array is one of the most common commercial microarrays used in human cancer profiling and contains 2448 probe sets for lncRNA genes [@B18]. In the current study, we combined two previously published GEO dataset to identify differentially expressed lncRNAs in TSCC. We found 12 differentially expressed lncRNAs in TSCC tissues when compared with the noncancerous tissue samples. The majority of these lncRNA transcripts have not been well characterized. These lncRNAs might participate in carcinogenesis and progression of TSCC and worth for further study. And more lncRNA microarray analysis may help to identify more valuable and effective lncRNA-based diagnosis, prognosis and therapeutic biomarkers. Among these 12 lncRNAs, H19 is a long non-coding RNA differentially expressed in many tumors and participates in tumorigenesis [@B50]-[@B53], it was also downregulated in TSCC samples compared with the adjacent non-tumor tissues. Until now, there were few reports about lncRNA H19 in head and neck squamous carcinoma [@B54], [@B55], and it might participate in the development of TSCC.

In this paper, we chose and focused on LINC00152, since it had the highest fold change among lncRNAs dysregulated in TSCC but never been reported in TSCC previously. We performed qRT-PCR and *in situ* hybridization to verify our results using existing data in the GEO database. We found LINC00152 was upregulated in TSCC and its high expression was associated with tumor progression, such as tumor size, invasion of muscles, lymph node metastasis, clinical stages, and recurrence. These results indicated the potential role of LINC00152 abnormalities in TSCC progression and potential value as diagnostic and prognostic factor in patients with TSCC. More and more research shows that tobacco and areca hobbies play an important role in the development of oral cancer [@B56], [@B57]. However, our result demonstrated that high LINC00152 expression was lacking correlations with smoking and areca hobbies, this may partly owing to the limited sample size.

Recent studies have reported that LINC00152 was upregulated in gastric and hepatocellular cancer [@B58]. It promoted tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 and participated in cell cycle arrest, apoptosis, epithelial to mesenchymal transition (EMT), cell migration and invasion in gastric cancer [@B59]. In addition, another research confirmed that LINC00152 contributed proliferation through the EGFR-dependent pathway in gastric cancer [@B59] or by targeting EpCAM via the mTOR signaling pathway in hepatocellular carcinoma [@B58]. Further exploring found that LINC00152 could also act as a circulating biomarker for the diagnosis of hepatocellular cancer [@B60]. To our knowledge, we are the first to report the prognostic values of LINC00152 in prediction of TSCC metastases. Further functional studies of LINC00152 will enrich our knowledge to understand the underlying mechanisms of TSCC metastases.

In conclusion, we found that LINC00152 was the most significantly upregulated lncRNA in TSCC, elevated LINC00152 expression was associated with poor prognosis, suggesting that LINC00152 was promising prognostic biomarkers of TSCC.
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![**Dysregulated lncRNA expression analysis using two independent TSCC cohorts and cDNA microarray analysis. A.**Schematic overview of the workflow used to identify dysregulated lncRNAs in two TSCC microarray data cohorts (GSE9844 and GSE30784). **B.**Heatmap of 12 dysregulated lncRNAs mined from the GEO data sets.](jcav08p0523g001){#F1}

![**LINC00152 expression was upregulated in three independent cohorts of TSCC biopsies.** T, tumor; N, non-tumor lingual mucous membrane. LINC00152 expression, as measured by Affymetrix microarray, was upregulated TSCC biopsies when compared with non-tumor lingual mucous membrane tissues in GSE30784 (**A**) and GSE9844 (**B**). **C**. LINC00152 mRNA expression was measured in 15 TSCC tissues and 14 adjacent non-tumor tissues using quantitative PCR (qRT-PCR).](jcav08p0523g002){#F2}

![**The relationship between LINC00152 and pathological clinical feature**. **A**. LINC00152 expression was measured by *in situ*hybridization in paraffin embedded non-tumor lingual mucous membrane (N, n = 46) and TSCC biopsies (T, n = 182). Representative cases of normal lingual mucous membrane (N) and TSCC biopsies were shown. **B**. LINC00152 expression in tumor compared to adjacent non-tumor lingual mucous membrane. **C**. Correlation of LINC00152 expression and tumor size in TSCC patients. **D**. Correlation of LINC00152 expression and lymph node metastasis in TSCC patients. **E**. Correlation of LINC00152 expression and TNM stage in TSCC patients. **F**. Correlation of LINC00152 expression and recurrence of TSCC patients. **G**. Correlation of LINC00152 expression and tongue muscle invasion in TSCC patients.](jcav08p0523g003){#F3}

![**Kaplan-Meier survival curves in TSCC patients according to LINC00152 expression levels.**The highly expressed LINC00152 was correlated with shorter overall survival (**A**) or Relapse free survival (**B**) of TSCC patients.](jcav08p0523g004){#F4}
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